Implications of Genetic Elements on Type 2 Diabetes Mellitus Pathogenesis and Management

Type 2 diabetes mellitus (T2DM) is a complex, multifactorial disease influenced by interactions between environmental exposures and genetic determinants. Increasing evidence highlights the important role of genetic variation in disease susceptibility, progression, and therapeutic response.

This review aims to explore key genetic factors associated with T2DM risk and pathogenesis, as well as pharmacogenomic variants that influence antidiabetic therapy metabolism and clinical response.

Several genetic variants have been linked to altered glucose metabolism and increased susceptibility to T2DM. Notable genes include KCNJ11, HNF4A, IGF2BP2, CDKN2A/B, PPARγ, KLF14, and IRS, which influence insulin secretion, insulin signalling, and glucose regulation. Genetic polymorphisms vary across populations and may contribute to differences in disease susceptibility. In addition, variations in drug-metabolising enzymes, particularly within the cytochrome P450 enzymes (CYP450), can influence the pharmacokinetics and pharmacodynamics of commonly prescribed antidiabetic medications. Some major CYP450 isoforms implicated in the metabolism of antidiabetic medications have been shown to exhibit polymorphisms that can alter plasma drug concentrations, ultimately leading to poor glycaemic control or heightening adverse effects.

Therefore, understanding these genetic underpinnings is critical for advancing precision medicine approaches in diabetes care, enabling tailored pharmacotherapy and optimising treatment outcomes. By integrating genetic insights into clinical decision-making, this paper highlights the potential of pharmacogenomics not only to identify populations at risk of developing T2DM but also to improve glycaemic control, reduce adverse drug reactions, and enhance patients' quality of life with T2DM.